Literature DB >> 20146217

Medulloblastoma in young children.

Stefan Rutkowski1, Bruce Cohen, Jonathan Finlay, Roberto Luksch, Vita Ridola, Dominique Valteau-Couanet, Junichi Hara, Maria-Luisa Garre, Jacques Grill.   

Abstract

In early childhood medulloblastoma, three distinct treatment strategies are currently used by different national groups to improve survival rates and to delay or avoid craniospinal radiotherapy: (1) systemic chemotherapy and high-dose chemotherapy, followed by radiotherapy at relapse; (2) systemic and intraventricular chemotherapy; (3) systemic chemotherapy and local conformal radiotherapy. A role for high-dose chemotherapy to delay or avoid craniospinal radiotherapy as a part of multimodal treatment strategies, especially in young children with metastatic or postoperative residual disease, has been recognized by different co-operative groups. Clinical and histological factors such as nodular-desmoplastic variants are considered as important prognostic factors for risk-adapted treatment recommendations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20146217     DOI: 10.1002/pbc.22372

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  22 in total

1.  Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.

Authors:  André O von Bueren; Katja von Hoff; Torsten Pietsch; Nicolas U Gerber; Monika Warmuth-Metz; Frank Deinlein; Isabella Zwiener; Andreas Faldum; Gudrun Fleischhack; Martin Benesch; Juergen Krauss; Joachim Kuehl; Rolf D Kortmann; Stefan Rutkowski
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT.

Authors:  Swapna Asuthkar; Arun Kumar Nalla; Christopher S Gondi; Dzung H Dinh; Meena Gujrati; Sanjeeva Mohanam; Jasti S Rao
Journal:  Neuro Oncol       Date:  2011-08-02       Impact factor: 12.300

3.  Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221).

Authors:  Lucie Lafay-Cousin; Eric Bouffet; Douglas Strother; Vasilisa Rudneva; Cynthia Hawkins; Charles Eberhart; Craig Horbinski; Linda Heier; Mark Souweidane; Chris Williams-Hughes; Arzu Onar-Thomas; Catherine A Billups; Maryam Fouladi; Paul Northcott; Giles Robinson; Amar Gajjar
Journal:  J Clin Oncol       Date:  2019-11-27       Impact factor: 44.544

4.  Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas.

Authors:  Wan-Yee Teo; M Tarek Elghetany; Jianhe Shen; Tsz-Kwong Man; Xiaonan Li; Murali Chintagumpala; Jack Meng Fen Su; Robert Dauser; William Whitehead; Adekunle M Adesina; Ching C Lau
Journal:  J Neurooncol       Date:  2014-08-13       Impact factor: 4.130

Review 5.  Brain tumors in children--current therapies and newer directions.

Authors:  Soumen Khatua; Zsila Sousan Sadighi; Michael L Pearlman; Sunil Bochare; Tribhawan S Vats
Journal:  Indian J Pediatr       Date:  2012-07       Impact factor: 1.967

Review 6.  Tumors of the central nervous system in children and adolescents.

Authors:  Michael C Frühwald; Stefan Rutkowski
Journal:  Dtsch Arztebl Int       Date:  2011-06-03       Impact factor: 5.594

7.  Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.

Authors:  Jacques Grill; Birgit Geoerger; Lyle Gesner; Danuta Perek; Pierre Leblond; Adela Cañete; Isabelle Aerts; Luis Madero; Josep Sanchez de Toledo Codina; Joris Verlooy; Edward Estlin; Laura Cisar; Aurora Breazna; Andrew Dorman; Simon Bailey; Gary Nicolin; Richard G Grundy; Darren Hargrave
Journal:  Neuro Oncol       Date:  2013-07-14       Impact factor: 12.300

Review 8.  SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature.

Authors:  Ross Mangum; Elizabeth Varga; Daniel R Boué; David Capper; Martin Benesch; Jeffrey Leonard; Diana S Osorio; Christopher R Pierson; Nicholas Zumberge; Felix Sahm; Daniel Schrimpf; Stefan M Pfister; Jonathan L Finlay
Journal:  Childs Nerv Syst       Date:  2016-07-21       Impact factor: 1.475

9.  Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma.

Authors:  Marc Remke; Esther Hering; Nicolas U Gerber; Marcel Kool; Dominik Sturm; Christian H Rickert; Joachim Gerß; Stefan Schulz; Thomas Hielscher; Martin Hasselblatt; Astrid Jeibmann; Volkmar Hans; Vijay Ramaswamy; Michael D Taylor; Torsten Pietsch; Stefan Rutkowski; Andrey Korshunov; Carmelia-Maria Monoranu; Michael C Frühwald
Journal:  Childs Nerv Syst       Date:  2013-05-16       Impact factor: 1.475

10.  Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: Impact on survival.

Authors:  Laura Negretti; Pierre Blanchard; Dominique Couanet; Virginie Kieffer; Gisele Goma; Jean Louis Habrand; Frédéric Dhermain; Dominique Valteau-Couanet; Jacques Grill; Christelle Dufour
Journal:  Neuro Oncol       Date:  2012-10-05       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.